Disclosures: Sharaiha reports consulting for Boston Scientific, Cook Medical, Lumenci and Olympus.
October 06, 2020
1 min read
Save

Endoscopic sleeve gastroplasty safe, effective for long-term obesity treatment

Disclosures: Sharaiha reports consulting for Boston Scientific, Cook Medical, Lumenci and Olympus.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patients with obesity treated with endoscopic sleeve gastroplasty achieved durable results for at least 5 year after the procedure, according to study results.

Reem Z. Sharaiha, MD, MSc, from the division of gastroenterology and hepatology at Weill Cornell Medicine, and colleagues wrote that endoscopic sleeve gastroplasty (ESG) is one of the most widely available endoscopic techniques for weight management, but more research is needed.

Endoscopic sleeve gastroplasty was a safe and effective treatment for obesity.
Endoscopic sleeve gastroplasty was a safe and effective treatment for patients with obesity.

“Given the relatively recent adoption of ESG by endoscopists, there are a lack of data on its long-term effectiveness beyond 2 years after the procedure,” they wrote. “This is an important gap in the current knowledge given the generally high relapse rates observed in virtually all treatments of obesity, and a concern for behavioral and anatomic adaptation and changes over time that can lead to regaining initial weight after ESG.”

Researchers prospectively enrolled 216 patients who underwent ESG at a single center and followed them for up to 5 years. Patients had a mean BMI of 39±6 kg/m2. The primary outcome of the study was weight loss at 5 years after the procedure measured by percent of total body weight loss (TBWL).

Of the overall study cohort, 203 patients were eligible for a 1-year follow-up, 96 were eligible for a 3-year follow-up and 38 were eligible for a 5-year follow-up.

At 5 years, the mean TBWL was 15.9% (95% CI, 11.7–20.5), while 90% of patients maintained 5% TBWL and 61% maintained 10% TBWL.

Researchers observed an overall rate of moderate adverse events of 1.3% and reported no severe or fatal adverse events.

“Our results suggest that ESG is safe and effective, with durable long-term results for at least up to 5 years after the procedure,” Sharaiha and colleagues wrote. “With a favorable safety profile, and 90% of patients benefiting from clinically significant weight loss 5 years after ESG, this procedure can and should be considered an established reliable option for treatment of obesity.”